For most people, elevated cholesterol is managed with diet, exercise, and medications such as statins. But for a smaller group of patients -often those with genetic conditions like familial hypercholesterolemia or very high lipoprotein(a) levels -standard treatments alone may not bring LDL cholesterol down to a safer range. This is where the relationship between cholesterol and plasmapheresis becomes clinically relevant. Plasmapheresis, and its more targeted variant known as LDL apheresis or lipoprotein apheresis, is a medical procedure that mechanically filters cholesterol-carrying particles out of the bloodstream when medication alone is not enough.
This article explains what plasmapheresis is, how it works specifically for cholesterol management, who research suggests may be considered a candidate, what a typical treatment course involves, and what the published evidence shows about its effectiveness and safety. As with any specialized medical procedure, plasmapheresis for cholesterol is not a first-line treatment and is used under close physician supervision, usually alongside -not instead of -standard lipid-lowering therapy.
How Plasmapheresis Works for Cholesterol Management
Plasmapheresis is a procedure in which blood is drawn from the body, run through a machine that separates plasma (the liquid component of blood) from red blood cells, white blood cells, and platelets, and returned along with a replacement fluid. In general therapeutic plasma exchange, the plasma itself is discarded and replaced with albumin or saline while the blood cells go back to the patient.
For cholesterol management specifically, most modern programs use a more selective process called LDL apheresis or lipoprotein apheresis rather than traditional plasma exchange. Instead of removing whole plasma, this method uses filtration columns, membrane separation, or precipitation techniques that selectively bind and remove LDL cholesterol and lipoprotein(a), or Lp(a), particles while returning the rest of the plasma -including beneficial proteins like albumin -to the patient. Techniques have included dextran sulfate cellulose adsorption, heparin-induced extracorporeal LDL precipitation, and double-filtration plasmapheresis. Because plasma is largely returned rather than discarded, this approach tends to reduce some fluid and protein-depletion risks associated with full plasma exchange while still achieving substantial LDL and Lp(a) reductions. Research on cascade filtration plasmapheresis has documented an acute LDL reduction of roughly 70% per session in patients with severe genetic hypercholesterolemia (Kardaş et al., Turkish Journal of Hematology, 2011). Our complete guide to plasmapheresis covers the broader procedure in more detail.
Who May Be a Candidate?
This procedure is not a routine or first-line therapy. It is generally reserved for patients whose cholesterol levels remain severely elevated despite maximally tolerated statin therapy, ezetimibe, and, where appropriate, PCSK9 inhibitors. Populations most frequently discussed in the clinical literature include:
- Individuals with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition in which LDL receptors are severely deficient or absent, often producing LDL cholesterol levels several times above normal from childhood.
- Individuals with severe heterozygous familial hypercholesterolemia who have documented coronary artery disease and whose LDL cholesterol remains markedly elevated despite maximal drug therapy.
- Patients with significantly elevated lipoprotein(a) and progressive cardiovascular disease, particularly when Lp(a)-lowering medication options are limited, since statins have little effect on Lp(a) levels.
- Select patients with refractory angina in the setting of elevated Lp(a), where apheresis has been studied as an adjunct to standard cardiac care (Khan et al., Antioxidants, 2021).
Whether plasmapheresis for high cholesterol is appropriate for a given patient is a decision made by a lipid specialist or cardiologist based on genetic testing, cardiovascular risk profile, and documented failure or intolerance of standard therapies. This information is general and educational; it is not a recommendation for any individual to pursue or avoid the procedure.
What to Expect During Treatment
A typical session takes place in a specialized clinical or hospital setting and generally lasts between two and four hours, depending on the technique used and the volume of blood processed. Patients are connected via IV access or, in some cases, a dedicated vascular access point for those undergoing long-term chronic treatment. Blood is withdrawn, processed through the separation and filtration system, and returned to the body in a continuous or intermittent cycle.
Because LDL and Lp(a) levels tend to rebound over the following one to two weeks, treatment is typically repeated on a regular schedule -commonly every one to two weeks -as chronic, ongoing management rather than a one-time intervention. Patients are monitored throughout each session for blood pressure changes, calcium levels, and signs of allergic reaction. Bloodwork before and after sessions typically tracks LDL cholesterol, Lp(a), and total cholesterol to evaluate how treatment is performing alongside a patient’s medication regimen.
The Evidence: What Research Shows
Lipoprotein apheresis has one of the longer track records of any extracorporeal therapy used in cardiovascular medicine, and the evidence generally supports both meaningful lipid reduction and, in some studies, improved cardiovascular outcomes.
In a randomized controlled trial of patients with heterozygous familial hypercholesterolemia and coronary artery disease, the Familial Hypercholesterolaemia Regression Study compared fortnightly LDL apheresis plus simvastatin to combination drug therapy alone. Over roughly two years, quantitative coronary angiography suggested the apheresis group had more favorable changes in coronary artery narrowing, supporting the idea that more aggressive LDL lowering may relate to atherosclerosis progression (Thompson et al., The Lancet, 199592961-4)).
A separate long-term study from the Hokuriku-FH-LDL-Apheresis Study Group followed patients with severe heterozygous familial hypercholesterolemia and coronary heart disease treated with chronic LDL apheresis versus drug therapy alone. The apheresis group had a substantially lower rate of total coronary events over follow-up, suggesting regular apheresis may be associated with a reduced burden of cardiac events in this high-risk population (Mabuchi et al., American Journal of Cardiology, 199800692-4)).
Longer-term registry data reinforce this pattern. An analysis of patients undergoing chronic LDL apheresis for severe hypercholesterolemia or isolated Lp(a) elevation with progressive cardiovascular disease found the average annual rate of major adverse cardiac events declined substantially after apheresis began, compared with the pre-treatment rate, in both subgroups (Heigl et al., Clinical Research in Cardiology Supplements, 2015).
More mechanistic research explores why apheresis may benefit patients beyond simple LDL lowering. A randomized, sham-controlled crossover trial in patients with refractory angina and elevated Lp(a) found that lipoprotein apheresis significantly reduced oxidized LDL and related antibody markers alongside large reductions in Lp(a) and LDL cholesterol, suggesting apheresis may reduce inflammatory and oxidative burden in the vessel wall beyond simply lowering lipid particle counts (Khan et al., Antioxidants, 2021).
Taken together, this research indicates that LDL apheresis is associated with substantial, reproducible reductions in LDL cholesterol and Lp(a), with several studies suggesting an association with reduced cardiovascular events in appropriately selected, high-risk patients. Much of this evidence comes from observational or registry-based data rather than large modern randomized outcome trials, so it is best interpreted as supportive rather than definitive.
Safety Considerations
LDL apheresis has an established safety profile in accredited centers, though it is not without risk. Commonly reported effects include transient hypotension, citrate-related calcium binding (tingling around the mouth or fingers), and mild anemia related to the extracorporeal circuit. Less commonly, patients may experience allergic reactions to the filtration membrane or replacement fluids, or vascular access complications, including infection risk with repeated catheter use.
Patients on ACE inhibitors may need temporary medication adjustment before certain apheresis techniques, since some methods have been linked to bradykinin-related reactions. Because treatment involves regular, ongoing sessions, candidates also need reliable vascular access. People with active infections, certain bleeding disorders, or hemodynamic instability are generally not considered appropriate candidates until those issues are addressed. All decisions about starting, continuing, or stopping this therapy should be made with a qualified lipid specialist or cardiologist familiar with the patient’s full medical history.
Frequently Asked Questions
What is the difference between plasmapheresis and LDL apheresis?
Plasmapheresis broadly refers to separating and removing plasma from blood, generally replacing it with albumin or saline. LDL apheresis is a more selective form of this technology that specifically targets and removes LDL cholesterol and Lp(a) particles while returning most other plasma components to the patient.
How much can plasmapheresis lower cholesterol?
Research on lipoprotein apheresis suggests it can acutely reduce LDL cholesterol by roughly 50% to 70% or more per session, though levels typically begin rising again within one to two weeks, which is why chronic treatment is repeated on a regular schedule rather than performed once (Kardaş et al., Turkish Journal of Hematology, 2011).
Is plasmapheresis for high cholesterol a permanent treatment?
No single session provides a lasting reduction. Because LDL and Lp(a) levels rebound over time, plasmapheresis for high cholesterol is generally used as an ongoing, repeated therapy for appropriately selected patients rather than a one-time cure, and it is typically combined with continued lipid-lowering medication.
Does insurance typically cover LDL apheresis?
Coverage varies by insurer, diagnosis, and region, and often requires documentation such as genetically confirmed familial hypercholesterolemia or very elevated Lp(a) with progressive cardiovascular disease despite maximal drug therapy. Patients should discuss coverage directly with their care team and insurer.
Can statins replace the need for plasmapheresis?
For most people with elevated cholesterol, statins and other lipid-lowering medications are effective and remain the first-line approach. LDL apheresis is reserved for the smaller group whose LDL or Lp(a) remains severely elevated despite maximally tolerated medication therapy.
Does lipoprotein apheresis treat lipoprotein(a) specifically?
Yes. Because Lp(a) is largely genetically determined and is not substantially lowered by most current medications, apheresis has been studied as a way to reduce circulating Lp(a) in patients with very high levels and progressive cardiovascular disease, with several studies reporting reductions of 60% to 70% or more per session.
Are there side effects during an apheresis session?
Reported effects can include temporary low blood pressure, tingling related to citrate anticoagulation, mild fatigue, and, less commonly, allergic reactions to the filtration system. Sessions are performed under clinical monitoring to identify and manage these effects promptly.
How is a candidate for cholesterol and plasmapheresis identified?
Identifying a candidate for cholesterol and plasmapheresis typically involves genetic or clinical diagnosis of familial hypercholesterolemia or confirmed markedly elevated Lp(a), documented cardiovascular disease or high cardiovascular risk, and evidence that maximally tolerated medications have not achieved target levels. This evaluation is made by a specialist, not through self-diagnosis.
Key Takeaways
- Cholesterol and plasmapheresis intersect through a specialized procedure called LDL or lipoprotein apheresis, which mechanically filters LDL cholesterol and Lp(a) particles out of the blood plasma.
- This approach is generally reserved for patients with familial hypercholesterolemia, severely elevated Lp(a), or statin-refractory high cholesterol with cardiovascular disease -not a first-line treatment for typical high cholesterol.
- The procedure works by separating plasma from blood cells and using selective filtration to remove cholesterol-carrying particles before returning treated plasma and blood cells to the patient.
- Because LDL and Lp(a) rebound within one to two weeks, treatment is typically repeated on an ongoing schedule rather than performed as a single session.
- Multiple studies, including a randomized angiographic trial and long-term registry data, suggest LDL apheresis is associated with reduced cardiovascular events in high-risk patients, though much of this evidence is observational.
- Reported risks include transient hypotension, citrate-related symptoms, and allergic reactions, and the procedure requires monitoring in an accredited clinical setting.
- Any decision about pursuing plasmapheresis for high cholesterol should be made with a lipid specialist or cardiologist, based on genetic testing, cardiovascular risk, and documented medication history.
Learn more about how plasmapheresis, also known as therapeutic plasma exchange, fits into a broader, personalized approach to cardiovascular and metabolic health, or schedule a consultation to discuss comprehensive lipid testing and whether further evaluation may be appropriate for you. For related reading on how plasma-based procedures are used in other conditions, see our article on how plasmapheresis helps autoimmune conditions.
References
- Thompson GR, Maher VM, Matthews S, et al. “Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.” The Lancet, 1995;345(8953):811-816. DOI: https://doi.org/10.1016/S0140-6736(95)92961-492961-4)
- Mabuchi H, Koizumi J, Shimizu M, et al., for the Hokuriku-FH-LDL-Apheresis Study Group. “Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia.” American Journal of Cardiology, 1998;82(12):1489-1495. DOI: https://doi.org/10.1016/S0002-9149(98)00692-400692-4)
- Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R. “Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.” Clinical Research in Cardiology Supplements, 2015;10(Suppl 1):8-13. DOI: https://doi.org/10.1007/s11789-015-0071-3
- Khan TZ, Hartley A, Haskard D, Caga-Anan M, Pennell DJ, Collins P, Barbir M, Khamis R. “Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).” Antioxidants, 2021;10(1):132. DOI: https://doi.org/10.3390/antiox10010132
- Kardaş F, Çetin A, Solmaz M, Büyükoğlan R, Kaynar L, Kendirci M, Eser B, Ünal A. “Successful Treatment of Homozygous Familial Hypercholesterolemia Using Cascade Filtration Plasmapheresis.” Turkish Journal of Hematology, 2011;29(4):334-341. DOI: https://doi.org/10.5152/tjh.2011.20
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member